Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Posters

Search Title by author or title

Use of cross-linking in refractory infectious keratitis: prospective study of 22 cases

Poster Details

First Author: S.Karmoun MOROCCO

Co Author(s):                        

Abstract Details

Purpose:

Infectious keratitis represents an important therapeutic emergency and requires a good use of efficient antimicrobial treatment on a large scale to protect vision. Nonetheless, this treatment becomes more difficult and less efficient due to microorganisms capacity to develop resistance to usual drugs. The purpose of our work is to evaluate the efficacy and safety of crosslinking (CXL) in refractory infectious keratitis

Setting:

A single centre prospective study was carried out on patients attending the ophthalmology B department of Avicenna University Hospital, Rabat, Morocco

Methods:

In our prospective study, we describe 22 cases of infectious keratitis refractory to conventional treatments within our service which has benefited from crosslinking in order to reduce healing time and improve visual prognosis. In our series the CXL was done via transepithelial pathway due to Medio-Cross Riboflavin/ Dextran solution 0.25% along with UVA according to intermediate protocol.

Results:

For 22 patients (14man/8women), we can notice a photophobia and lacrimation decrease within 48 hours following the CXL session to all cases. One week after CXL associated with ATB treatment, we notice a net ulcer improvement for 18 eyes, a rapid and net reduction of edema and corneal ulcer diameter along with a progressive improvement of visual acuity. M├ęthillino aureus resistant staphylococcus is on the top of germs that have been found.

Conclusions:

Transepithelial CXL could be a new method in the treatment of infectious keratitis refractory to usual treatments and could be even used as first intention due to resistant strains frequency.

Financial Disclosure:

None

Back to Poster listing